[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
December 5, 2001

Oral Sodium Phosphate

Author Affiliations
 

Not Available

Not Available

JAMA. 2001;286(21):2660. doi:10.1001/jama.286.21.2660-JFD10012-2-1

The FDA has conducted a safety review on oral sodium phosphate using the agency's databases and medical literature. The review shows that serious electrolyte disturbances (hypernatremia, hypokalemia, hyperphosphatemia, and hypocalcemia), dehydration, metabolic acidosis, renal failure, tetany, and death have been attributed to patients receiving more than a 45-mL dose of oral sodium phosphate (usually a minimum of 90 mL during a 24-hour period). Changes in hematocrit, serum sodium, blood urea nitrogen, serum osmolality, and body weight after ingesting sodium phosphate oral solution suggest that a mild contraction of intravascular volume can occur in this population.

First Page Preview View Large
First page PDF preview
First page PDF preview
×